Abeona Therapeutics Inc.
ABEO
Rank in Stocks
#18077
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical... Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Share Price
$2.54
Last synced: 2026-11-09
Market Cap
$145.25M
Change (1 day)
-39.09%
Change (1 year)
-39.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Abeona Therapeutics Inc. (ABEO)
Category
Healthcare
Operating Margin for Abeona Therapeutics Inc. (ABEO)
Operating Margin as of November 2026 TTM: -327.64%
According to Abeona Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is -327.64%. At the end of 2025 the company had an operating margin of -1,536.91%.
Operating Margin history for Abeona Therapeutics Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -327.64% | -78.68% |
| 2025 | -1,536.91% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -1,346.71% | -62.60% |
| 2022 | -3,600.78% | 20.25% |
| 2021 | -2,994.53% | 267.79% |
| 2020 | -814.20% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -1,940.16% | -41.66% |
| 2017 | -3,325.69% | 23.80% |
| 2016 | -2,686.28% | 50.64% |
| 2015 | -1,783.27% | 426.83% |
| 2014 | -338.49% | 81.70% |
| 2013 | -186.29% | 90.09% |
| 2012 | -98.00% | -77.01% |
| 2011 | -426.19% | -73.57% |
| 2010 | -1,612.68% | -41.33% |
| 2009 | -2,748.86% | -52.71% |
| 2008 | -5,812.71% | -51.98% |
| 2007 | -12,105.26% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | -100.00% |
| 2004 | -1,093.44% | 160.96% |
| 2003 | -419.00% | -44.76% |
| 2002 | -758.50% | -70.78% |
| 2001 | -2,595.88% | -54.15% |
| 2000 | -5,661.68% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.55% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Abeona Therapeutics Inc.'s operating margin
What is Abeona Therapeutics Inc.'s operating margin?
Abeona Therapeutics Inc.'s operating margin is -327.64%, as of Nov 2026.
What was Abeona Therapeutics Inc.'s operating margin in 2025?
In 2025, Abeona Therapeutics Inc.'s operating margin was -1,536.91%, compared with 0.00% in 2024.
How has Abeona Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, Abeona Therapeutics Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2022 (-3,600.78%).
How does Abeona Therapeutics Inc.'s operating margin compare with similar companies?
Abeona Therapeutics Inc.'s operating margin (-327.64%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.